Abstract
We compared the in vitro activity of BMS-181184, the first compound of a new class of antifungal agents, the pradimicins, with those of fluconazole and amphotericin B against 64 clinical isolates of Candida species, MICs were determined by a microdilution method with high resolution medium for BMS- 181184 and fluconazole and antibiotic medium no. 3 with 2% glucose for amphotericin B. MICs of BMS-181184 for all yeasts were in the range of 0.78 to 12.5 μg/ml. BMS-181184 was active against isolates resistant to other antifungal agents, consistent with a novel mode of action. Minimum fungicidal concentrations for 16 isolates showed that BMS-181184 was fungicidal. Clinical studies are now required to confirm its activity.
| Original language | English |
|---|---|
| Pages (from-to) | 2229-2231 |
| Number of pages | 3 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 40 |
| Issue number | 9 |
| Publication status | Published - 1 Sept 1996 |
Fingerprint
Dive into the research topics of 'In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various Candida spp.'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver